Brief: Bayer Says China's Center Of Drug Evaluation Grants Priority Review Designation For Asundexian
07/05/2026 09:53
May 7 (Reuters) - BAYER AG BAYGn.DE: CHINA'S CENTER OF DRUG EVALUATION GRANTS PRIORITY REVIEW DESIGNATION FOR ASUNDEXIAN Further company coverage: [BAYGn.DE] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com ; +48 587785269;;))
Recent news on Bayer AG
See all newsBayer takes a giant leap toward investability
Europe Research Roundup: Barratt Redrow, Ferrari, KPN
Explainer: What does Bayer's US Supreme Court win mean for the thousands of Roundup lawsuits?
Bayer shares soar over 18% after U.S. Supreme Court curbs Roundup lawsuits
US Supreme Court scales back Roundup cancer suits in win for Bayer (updated)